No Data
Shenzhen Kangtai Biological Products (300601.SZ): Termination of the implementation of the 2023 Stock Options and Restricted Stock Incentive Plan, as well as the cancellation of Stock Options and invalidation of Restricted Stocks.
On December 31, Gloronghui reported that Shenzhen Kangtai Biological Products (300601.SZ) announced that due to significant changes in the current Industry environment, market Operation environment, and other internal and external factors compared to those when the company launched the 2023 Stocks Options and Restricted Stock Incentive Plan, it will be difficult to achieve the expected incentive objectives and effects by continuing to implement this incentive plan. To better protect the interests of the company, Shareholders, and employees, and based on the actual situation of the company and future development plans, after careful study, the company intends to terminate the implementation of this incentive plan, cancel the Options, and invalidate the Restricted Stocks.
Shenzhen Kangtai Biological Products (300601.SZ): Some fundraising projects have been completed, and the surplus funds will be permanently used to supplement working capital.
On December 31, Gelonghui reported that Shenzhen Kangtai Biological Products (300601.SZ) announced it will hold the 25th meeting of the 7th Board of Directors and the 19th meeting of the 7th Supervisory Board on December 31, 2024. The meetings approved the proposal to conclude the projects of issuing convertible corporate bonds to unspecified objects and to permanently supplement the remaining raised funds for working capital. In light of the completion of the projects funded by the raised capital from issuing convertible corporate bonds to unspecified objects, namely the 'Baiwangxin Emergency Engineering & Construction Project' and the 'Adenovirus Vaccine Workshop Project'.
Does Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Weak Fundamentals Mean That The Market Could Correct Its Share Price?
Shenzhen Kangtai Biological Products (300601.SZ): Minhai Biological's 20-valent pneumococcal polysaccharide conjugate vaccine initiates Phase I clinical trials.
Great Long Special Report, November 25th| Shenzhen Kangtai Biological Products (300601.SZ) announced that its wholly-owned subsidiary, Peking Minhai Biological Technology Co., Ltd. (hereinafter referred to as "Minhai Biological"), has completed the preparation for Phase I clinical trial of the 20-valent pneumococcal polysaccharide conjugate vaccine developed, initiated the Phase I clinical trial, and recently successfully completed the first subject's enrollment. The 20-valent pneumococcal polysaccharide conjugate vaccine is suitable for infants and children aged 2 months to 5 years old. After vaccination with this vaccine, the body can generate an immune response to prevent infectious diseases caused by 20 serotypes of pneumococcal serotypes. Currently, the 20-valent pneumococcal polysaccharide conjugate vaccine has been marketed overseas.
Shenzhen Kangtai Biological Products (300601.SZ): The clinical trial application for bivalent inactivated rotavirus vaccine (Vero cells) has been accepted.
Announcement from shenzhen kangtai biological products (300601.SZ), the company's wholly-owned subsidiary Peking Minhai Biotechnology Co., Ltd. (referred to as "...
Shenzhen Kangtai Biological Products' (SZSE:300601) Profits Appear To Have Quality Issues
The Three-year Shareholder Returns and Company Earnings Persist Lower as Shenzhen Kangtai Biological Products (SZSE:300601) Stock Falls a Further 4.4% in Past Week
